---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-017916"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:59:37.009000+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharma reports Telomir-1 kills pancreatic cancer cells in vitro; plans further studies

## Summary
- Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in concentration-dependent manner.
- Effects partially reversed by iron re-addition, suggesting iron-dependent processes contribute to response.
- Telomir-1 previously shown to influence tumor suppressor genes and iron-dependent histone demethylases relevant to pancreatic cancer.
- Pancreatic cancer has five-year survival rate of ~12%; current treatments limited by toxicity and resistance.
- Telomir plans to expand preclinical research to leukemia models and initiate in vivo validation studies for IND preparation.

## SEC filing metadata
- accession: 0001493152-25-017916
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225017916/0001493152-25-017916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225017916/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-017916
- JSON: https://secwatch.observer/filing/0001493152-25-017916.json
- Plain text: https://secwatch.observer/filing/0001493152-25-017916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.